Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial after showing positive results in an earlier study.
The biotech company is hoping its shot, mRNA-1083, can win approval from regulators in 2025.
Only 20% of Americans eligible for COVID-19 boosters get them, and today in Vaccine,researchers published the results of a new survey of 2,000 US adults to understand why uptake is so low.
This vaccine is effective against EG.5, the currently dominant coronavirus strain in the United States, and like Pfizer and Moderna’s mRNA vaccines, it has been updated to target the XBB Omicron subvariant.
This week, studies in Morbidity and Mortality Weekly Report describe the landscape of COVID-19 vaccination among women of reproductive age and those who are pregnant, showing better outcomes for infants whose mothers were vaccinated during pregnancy.
Recent Comments